Nurix Therapeutics, Inc. (NRIX) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Study Overview: Nurix Therapeutics, Inc. (NRIX) is currently conducting a Phase 2 clinical trial, titled A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton’s Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i). The study aims to evaluate the safety and efficacy of NX-5948 for treating patients whose CLL/SLL has progressed following prior exposure to BTK and BCL-2 inhibitors, addressing a significant unmet medical need.
Intervention/Treatment: The trial focuses on NX-5948, an experimental drug designed for once-daily oral administration in 28-day cycles. The treatment aims to provide a targeted option for those with relapsed or refractory CLL/SLL after previous therapies.
Study Design: This interventional study follows a single-group, open-label model without masking. All participants receive the NX-5948 treatment, with the primary focus on assessing its therapeutic benefit in a highly specific patient group.
Study Timeline: Recruitment is actively ongoing, with the study’s initial submission date listed as October 24, 2025, and the most recent update recorded on December 16, 2025. While key completion dates have not been disclosed, the study is expected to span up to five years for participants, depending on disease progression.
Market Implications: Positive updates or preliminary results from this study could bolster Nurix Therapeutics’ stock performance, as investors monitor the potential of NX-5948 to address treatment-resistant cases of CLL/SLL. Competing companies in the hematologic oncology space may also be influenced by advances in targeted therapies, increasing interest in this niche segment of drug development.
This clinical trial remains ongoing, with further details available on the ClinicalTrials.gov portal under the identifier NCT07221500.
To learn more about NRIX’s potential, visit the Nurix Therapeutics, Inc. drug pipeline page.